Replies to post #2909 on Ariad Pharmaceuticals Inc fka ARIA

[BTH]

WAY overvalued comment.

If they decide to pull the "risk trade", this thing is way overvalued.

(look at what happened when they took risk off the table over the summer - it went back to 2.50, and that was before The Harv diluted the company 14%).

What amazes me is this: I am assuming The Harv didn't get what he was looking for with Ponatinib so he decided to dilute the company 14%. He played this same game with AP-23573 - until that game was up and he had to settle for giving 50% of the rights away GLOBALLY for the drug. The thing that amazes me is, when you have a company like Incyte (or even a worse company like Exelixis), and the amount of money they are getting upfront for their compounds!!! Either, Ariad's drugs aren't what we all would like them to believe they are, or The Harv is the laughing stock of bio-pharma and people know if they wait around long enough, they will get what they want.